Scancell Holdings PLC banner
Financial profile · FY2026

A pre-commercial biotech reliant on R&D investment and episodic funding

Scancell has no product-sales revenue and recurring operating losses as it funds clinical and platform development. Collaboration receipts are episodic, and the history shows reliance on equity, debt, and licensing to supplement operating cash needs.

What is developing

For the year ended April 30, 2026, licensing revenue disappeared and the operating loss widened even as R&D expense fell. This reinforces the episodic nature of collaboration income and shows that lower development costs have not yet produced operating breakeven.

What matters next

Whether the remaining merger-linked financing closes and provides usable cash for continued clinical development.

GBP
Metric FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026
(4.5m) (4.9m) (6.7m) (6.8m) (16.8m) (3.8m) (14.3m) (9.1m) (15.3m) (20.2m)
30k 30k 20k 40k 250k 740k 900k 966k 879k 672k
52k — — 10k 333k 690k 728k 660k 1.4m 1.8m
0 (70k) (270k) (20k) 8.3m (8.8m) 3.1m (8.5m) 1.7m 4.6m
(640k) (750k) 0 (1.8m) 0 (1.3m) (1.2m) (1.7m) (5.6m) (3m)
— — — — — 540k 540k 595k 43k 76k
620k 920k (70k) 2m 450k 1.7m 2.2m 1m 6.3m 4.2m
(3.9m) (4.1m) (7m) (4.8m) (7.8m) (10.2m) (8.1m) (15.7m) (6.4m)
(60k) (10k) 0 (30k) (740k) (1.3m) (200k) (177k) (1.5m)
50k 0 20k 10k 0 0 280k 355k 336k 750k
(10k) (10k) 10k (10k) (740k) (1.3m) 80k 178k (1.2m) 656k
0 12.5m 1.4m 3.9m 24.1m 0 170k 12m 11.3m 81k
— — — (30k) 23.4m (390k) (380k) (357k) (851k) (1.4m)
0 (840k) (80k) (50k) (1.4m) (540k) (540k) (1.2m) (741k) (76k)
0 11.7m 1.3m 3.8m 46.1m (930k) (750k) 10.4m 9.7m (1.4m)
— — — — — — — (11k) (11k) (15k)
(3.9m) 7.6m (5.7m) (980k) 37.5m (12.4m) (8.8m) (5.1m) 2.1m (11.6m)
(3.9m) (4.1m) (7m) (4.8m) (8.5m) (11.5m) (8.3m) (15.8m) (7.9m)